Endoplasmic reticulum-targeted NIR-II phototherapy combined with inflammatory vascular suppression elicits a synergistic effect against TNBC
Source abstract
Abstract
Recurrence and metastasis are the main reasons for failure in the treatment of triple-negative breast cancer (TNBC). Phototherapy, one of the most well-known potent cancer treatment models is highlighted by ablating primitive tumors with immunogenic cell death (ICD) and is associated with endoplasmic reticulum (ER) stress to elicit long-lasting anti-tumor immunity. However, the provoked inflammatory response after phototherapy will stimulate angiogenesis, which provides nutrition for tumor recurrence. Here, an ER-targeted nanoplatform was constructed based on hollow mesoporous Cu2-XS (HMCu2-XS) nanoparticles to suppress recurrence and metastasis of TNBC by combining photo-ablation and microenvironment remodeling. Profiting from the metal ion coordination and large hollow space, HMCu2-XS can be easily modified with p-toluenesulfonamide for ER-targeting and quantitatively loaded celecoxib (CXB) as a vascular inhibitor, thus obtaining ER-HMCu2-XS/CXB. ER-HMCu2-XS showed great photothermal and photodynamic efficiency for ablating 4T1 tumors and inducing ICD under NIR-II laser irradiation. Compared with non-ER-targeted nanosystems, the ER-targeted nanosystem elicited stronger ICDs and recruited more immune cells. Moreover, the thermal-responsively released CXB successfully inhibited angiogenesis after photothermal therapy. The data showed that the ER-HMCu2-XS/CXB mediated the triplicate therapeutic effect of photo-ablation, immune response activation, and vascular suppression effectively, preventing the recurrence and metastasis of TNBC. In conclusion, this work provides a synergistic strategy to enhance therapeutic outcomes in TNBC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Heme Oxygenase-1 and Carbon Monoxide · Retinal and Optic Conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The Key Laboratory of Biomedical Material, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China
The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China
Xuzhou Central Hospital, Xuzhou 221009, China
Funding
Xinxiang Medical University · National Natural Science Foundation of China
References (64)
Show source-provided references
1. Siegel · CA Cancer J. Clin. · 2022 · 72 · 710.3322/caac.21708 ↗
2. Zhang · Int. J. Oncol. · 2022 · 61 · 9510.3892/ijo.2022.5385 ↗
3. Huang · Sci. Adv. · 2020 · 6 · eaax503210.1126/sciadv.aax5032 ↗
4. Le · Nat. Commun. · 2018 · 9 · 217510.1038/s41467-018-04567-0 ↗
5. Jin · Biomaterials · 2021 · 268 · 12058210.1016/j.biomaterials.2020.120582 ↗
6. Qian · J. Mater. Sci. Technol. · 2022 · 127 · 24510.1016/j.jmst.2022.04.015 ↗
7. Wu · Biomater. Sci. · 2022 · 10 · 626710.1039/D2BM00803C ↗
8. Lv · Biomater. Sci. · 2022 · 10 · 478510.1039/D2BM00661H ↗
9. Jung · J. Am. Chem. Soc. · 2017 · 139 · 997210.1021/jacs.7b04263 ↗
10. Li · Adv. Mater. · 2021 · 33 · e200848110.1002/adma.202008481 ↗
11. Wang · Nano Today · 2021 · 40 · 10126610.1016/j.nantod.2021.101266 ↗
12. Yue · ACS Nano · 2021 · 15 · 1516610.1021/acsnano.1c05618 ↗
13. Li · ACS Appl. Mater. Interfaces · 2020 · 12 · 3007710.1021/acsami.0c06144 ↗
14. Ruttala · J. Mater. Sci. Technol. · 2021 · 86 · 13910.1016/j.jmst.2021.01.035 ↗
15. Nirmal · Biomater. Sci. · 2022 · 10 · 617210.1039/D2BM00835A ↗
16. Hai · ACS Appl. Nano Mater. · 2019 · 3 · 56310.1021/acsanm.9b02119 ↗
17. Wu · Adv. Healthcare Mater. · 2020 · 9 · e190130710.1002/adhm.201901307 ↗
18. Wang · ACS Nano · 2015 · 9 · 178810.1021/nn506687t ↗
19. Feng · Nanoscale · 2017 · 9 · 1568510.1039/C7NR05003H ↗
20. Gao · Adv. Funct. Mater. · 2021 · 31 · 210670010.1002/adfm.202106700 ↗
21. Zhang · Nanoscale · 2019 · 11 · 760010.1039/C9NR01789E ↗
22. Wang · ACS Appl. Mater. Interfaces · 2019 · 11 · 1636710.1021/acsami.9b03541 ↗
23. Xu · Chem. Soc. Rev. · 2021 · 50 · 111110.1039/D0CS00664E ↗
24. Jiang · Nat. Commun. · 2021 · 12 · 74210.1038/s41467-021-21047-0 ↗
25. Xu · Adv. Mater. · 2021 · 33 · e210141010.1002/adma.202101410 ↗
26. Spang · Curr. Opin. Cell Biol. · 2018 · 53 · 9210.1016/j.ceb.2018.06.004 ↗
27. Garg · Photochem. Photobiol. Sci. · 2014 · 13 · 47410.1039/c3pp50333j ↗
28. Shi · J. Controlled Release · 2021 · 329 · 33710.1016/j.jconrel.2020.11.054 ↗
29. Liu · Int. J. Nanomed. · 2020 · 15 · 67510.2147/IJN.S226186 ↗
30. He · J. Drug Targeting · 2021 · 29 · 1210.1080/1061186X.2020.1797051 ↗
31. Wan · Chem. Eng. J. · 2020 · 380 · 12245810.1016/j.cej.2019.122458 ↗
32. Zhou · Nat. Commun. · 2020 · 11 · 618310.1038/s41467-020-19945-w ↗
33. Zhang · Nanoscale Horiz. · 2020 · 5 · 48110.1039/C9NH00643E ↗
34. Liu · Nat. Commun. · 2022 · 13 · 217910.1038/s41467-022-29872-7 ↗
35. Li · Acta Biomater. · 2022 · 146 · 35710.1016/j.actbio.2022.05.014 ↗
36. Hanahan · Cancer Discovery · 2022 · 12 · 3110.1158/2159-8290.CD-21-1059 ↗
37. Xiao · Front. Oncol. · 2022 · 12 · 103937810.3389/fonc.2022.1039378 ↗
38. Bao · Theranostics · 2021 · 11 · 595510.7150/thno.58164 ↗
39. Khan · Nat. Rev. Clin. Oncol. · 2018 · 15 · 31010.1038/nrclinonc.2018.9 ↗
40. Du · J. Mater. Chem. B · 2021 · 9 · 721610.1039/D1TB00337B ↗
41. Hu · Biomaterials · 2019 · 206 · 10110.1016/j.biomaterials.2019.03.014 ↗
42. Deng · Nano Lett. · 2020 · 20 · 192810.1021/acs.nanolett.9b05210 ↗
43. Wang · Chin. Chem. Lett. · 2022 · 33 · 79310.1016/j.cclet.2021.08.087 ↗
44. Li · Adv. Funct. Mater. · 2020 · 30 · 200053210.1002/adfm.202000532 ↗
45. Xi · Adv. Mater. · 2020 · 32 · e190785510.1002/adma.201907855 ↗
46. Cheng · ACS Nano · 2020 · 14 · 1516110.1021/acsnano.0c05392 ↗
47. Wan · J. Nanobiotechnol. · 2021 · 19 · 34710.1186/s12951-021-01094-x ↗
48. Wang · ACS Cent. Sci. · 2020 · 6 · 55510.1021/acscentsci.9b01342 ↗
49. Ray · EMBO J. · 2007 · 26 · 336010.1038/sj.emboj.7601774 ↗
50. Orgaz · Cancer Cell · 2020 · 37 · 8510.1016/j.ccell.2019.12.003 ↗
51. Li · Sci. China: Chem. · 2020 · 63 · 1428
52. Panaretakis · EMBO J. · 2009 · 28 · 57810.1038/emboj.2009.1 ↗
53. Li · Nat. Commun. · 2019 · 10 · 334910.1038/s41467-019-11269-8 ↗
54. Mao · Sci. Adv. · 2020 · 6 · eabb271210.1126/sciadv.abb2712 ↗
55. Nam · Nat. Commun. · 2018 · 9 · 107410.1038/s41467-018-03473-9 ↗
56. Kenry · Adv. Mater. · 2018 · 30 · e180239410.1002/adma.201802394 ↗
57. Wang · Chem. Eng. J. · 2022 · 442 · 13632210.1016/j.cej.2022.136322 ↗
58. Chen · Adv. Mater. · 2022 · 34 · e220170610.1002/adma.202201706 ↗
59. Ma · Immunity · 2013 · 38 · 72910.1016/j.immuni.2013.03.003 ↗
60. Zhou · Clin. Cancer Res. · 2018 · 24 · 533510.1158/1078-0432.CCR-18-1126 ↗
61. Wang · Nano Lett. · 2020 · 20 · 627210.1021/acs.nanolett.0c01415 ↗
62. Zhang · Adv. Mater. · 2019 · 31 · e180593610.1002/adma.201805936 ↗
63. Feng · Adv. Funct. Mater. · 2021 · 31 · 210129710.1002/adfm.202101297 ↗
64. Scimeca · Mater. Today Adv. · 2022 · 15 · 10026010.1016/j.mtadv.2022.100260 ↗